GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » EV-to-FCF

Alere (ALRPRB.PFD) EV-to-FCF : 118.14 (As of Jun. 07, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Alere EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2017 was $33.89 Mil. Therefore, Alere's EV-to-FCF for today is 118.14.

The historical rank and industry rank for Alere's EV-to-FCF or its related term are showing as below:

ALRPRB.PFD's EV-to-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.02
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), Alere's stock price is $402.00. Alere's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was $0.000. Therefore, Alere's PE Ratio for today is N/A.


Alere EV-to-FCF Historical Data

The historical data trend for Alere's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere EV-to-FCF Chart

Alere Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alere Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alere's EV-to-FCF

For the Diagnostics & Research subindustry, Alere's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alere's EV-to-FCF falls into.



Alere EV-to-FCF Calculation

Alere's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4003.789/33.89
=118.14

Alere's current Enterprise Value is $4,003.79 Mil.
Alere's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alere  (NYSE:ALRPRB.PFD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alere's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=402.00/0.000
=N/A

Alere's share price for today is $402.00.
Alere's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Alere EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Alere's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere (ALRPRB.PFD) Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere (ALRPRB.PFD) Headlines

From GuruFocus

Diamond Hill Select Fund Third Quarter 2014 Commentary

By Vera Yuan Vera Yuan 10-17-2014

Alere Inc.: Foreign Currency Translations and the Euro

By Carmine Romano Carmine Romano 12-21-2011

Prem Watsa Trims IBM, Berkshire Hathaway

By Tiziano Frateschi Tiziano Frateschi 02-26-2018

Corsair Capital's Investment Thesis on Alere Inc.

By Canadian Value Canadian Value 01-23-2014

Mario Gabelli Comments on Alere Inc

By Vera Yuan Vera Yuan 11-21-2014

Mario Gabelli's Asset Fund Q3 2014 Commentary

By Vera Yuan Vera Yuan 11-21-2014

5 Resilient Biotech Stocks to Buy for 2012

By Vatalyst.com Vatalyst.com 02-28-2012

3 Investors Sitting on Huge Cash Stockpiles

By Holly LaFon Holly LaFon 11-21-2017

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 03-17-2015